<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43304">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542605</url>
  </required_header>
  <id_info>
    <org_study_id>20140207</org_study_id>
    <nct_id>NCT02542605</nct_id>
  </id_info>
  <brief_title>To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients</brief_title>
  <official_title>Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to
      Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced
      Migraine-like Attacks in Migraine Patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2015</start_date>
  <completion_date type="Anticipated">May 9, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of a migraine-like attack within 24 hours of challenge agent infusion</measure>
    <time_frame>1 day</time_frame>
    <description>Occurrence of a migraine-like attack within 24 hours of challenge agent infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a headache within 24 hours of challenge-agent infusion</measure>
    <time_frame>1 day</time_frame>
    <description>Occurrence of a headache within 24 hours of challenge-agent infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>85 days</time_frame>
    <description>Treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical significant changes in vital signs, ECGs, physical examinations, laboratory safety tests and neurological assessments</measure>
    <time_frame>85 days</time_frame>
    <description>Clinical significant changes in vital signs, ECGs, physical examinations, laboratory safety tests and neurological assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMG 334 PK parameters, including C1 hour and AUC0-85</measure>
    <time_frame>85 days</time_frame>
    <description>AMG 334 PK parameters, including C1 hour and AUC0-85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-AMG 334 antibodies</measure>
    <time_frame>85 days</time_frame>
    <description>Anti-AMG 334 antibodies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>AMG 334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PACAP-38 Challenge Agent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 334</intervention_name>
    <description>AMG 334 Investigational Product</description>
    <arm_group_label>AMG 334</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PACAP-38 Challenge Agent</intervention_name>
    <description>PACAP-38 challenge agent</description>
    <arm_group_label>PACAP-38 Challenge Agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥ 18 to ≤ 45 years of age upon entry into screening

          -  History of migraine headaches without aura for ≥ 6 months prior to screening
             according to the IHS Classification ICHD-II (Headache Classification Committee of the
             International Headache Society, 2004) based on medical records and/or patient
             self-report

          -  Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior
             to screening

        Exclusion Criteria:

          -  History of migraine with aura, cluster headache or hemiplegic migraine headache
             according to the IHS Classification ICHD-II (Headache Classification Committee of the
             International Headache Society, 2004) based on medical records and/or patient
             self-report

          -  ≥ 6 migraine days per month in the last 3 months prior to study enrollment and during
             screening period

          -  Other headache disorders (except for episodic tension-type headache &lt;5 days/month)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>September 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Headache</keyword>
  <keyword>Migraine Headache</keyword>
  <keyword>Headache, Migraine</keyword>
  <keyword>Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
